What was studied?
REDEFINE 2 randomized 1,206 adults with overweight or obesity and type 2 diabetes to cagrilintide-semaglutide or placebo, with lifestyle intervention, for 68 weeks.
What did the researchers report?
The combination group had greater average weight reduction and improved glycemic measures. Gastrointestinal adverse events were reported more often with the combination than with placebo.
What are the limits?
The trial compared the combination with placebo, not each component separately. It therefore cannot by itself isolate the contribution of each component, and its diabetes population should not be conflated with other trials.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.